Thus, the impact of personalized medicine in the short term might be positive at the patient’s bedside, but vast clinical trials to demonstrate the safety of new drugs will impose huge development costs that manufacturers might never recover. (Currently, only about one in five drugs approved by US regulators ever recoup their development costs.)&#160;This situation would not be sustainable in the long term.
因此，个性化用药的影响从短期看有利于病患方，但用大量临床试验来证明新药的安全性将给制药方带来巨大的开发成本。（现在，只有大约五分之一被美国监管者批准的药物能够收回开发成本。）从长期看，这一状况是不可持续的。